Dr. Jan Vorwerk is a distinguished medical researcher and clinician currently serving as a resident physician and clinician scientist at the Department of Hematology and Oncology, University Cancer Center Schleswig-Holstein (UCCSH), Germany. With a summa cum laude distinction for his medical doctorate and over five years of advanced medical training across Germany, Canada, and Switzerland, Dr. Vorwerk has made remarkable contributions to hematology and oncology research, particularly in acute myeloid leukemia (AML).
Profile
Scopus
Education 🎓
Dr. Vorwerk completed his Medical Doctorate at the University of Münster, with a groundbreaking thesis on the role of GFI1-36N polymorphism in DNA repair and AML therapy, earning summa cum laude honors. He is also a proud alumnus of the University of Zürich and McMaster University. His rigorous academic journey includes first-class grades in multiple state exams and prestigious scholarships from organizations like the German Academic Scholarship Foundation.
Experience 🏥
Dr. Vorwerk’s professional journey includes significant roles as a scholar at the Jürgen Manchot Foundation and the Interdisciplinary Center for Clinical Research Münster. Currently, he is at the forefront of clinical and molecular research in oncology as a resident physician at UCCSH, where he integrates cutting-edge therapies with patient care.
Research Interests 🔬
Dr. Vorwerk specializes in molecular hematology and oncology, focusing on the genetic and metabolic underpinnings of acute myeloid leukemia (AML). His research explores polymorphisms affecting DNA repair, mitochondrial function, and innovative therapeutic targets like CDK4/6 inhibition in leukemia and multiple myeloma.
Awards 🏆
Dr. Vorwerk has been recognized with numerous accolades, including the “Anne Frank Ambassador Award” for academic excellence and community leadership, the “Abitur Graduate Prize” from North Rhine-Westphalia, and scientific honors like the “Young People’s Award” and multiple international science fair prizes.
Publications Top Notes: 📚
Dr. Vorwerk has authored several impactful publications:
Presence of the GFI1-36N single nucleotide polymorphism enhances the response of MLL-AF9 leukemic cells to CDK4/6 inhibition. Front Oncol. 2022;12:903691.
Germline single-nucleotide polymorphism GFI1-36N causes alterations in mitochondrial metabolism and leads to increased ROS-mediated DNA damage in AML. Biomedicines. 2025;13:107.
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to therapy. Blood. 2023;142(25):2175-2191.